NCT03019289 - A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 19, 2017

Primary Completion Date

February 9, 2018

Study Completion Date

February 9, 2018

Conditions

Health Volunteers, Huntington Disease

Interventions

DRUG

pridopidine (90 mg)

single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.

Trial Locations (1)

04103

Teva Investigational Site 32648, Leipzig